a clear trendp = 0.09
However, the interim analysis showed a clear trend towards improved primary endpoint outcomes in the ECMO group vs. the standard therapy group, with 65% vs. 54% 60-day survival, respectively ( p = 0.09).
However, the interim analysis showed a clear trend towards improved primary endpoint outcomes in the ECMO group vs. the standard therapy group, with 65% vs. 54% 60-day survival, respectively ( p = 0.09).
Regrettably, the trial stopped prematurely because the difference between the groups did not reach statistical significance regarding the primary endpoint of 60-day mortality.